Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2022

Murthy, Neil; Wodi, A Patricia; Bernstein, Henry H.; McNally, Veronica; Cineas, Sybil; Ault, Kevin A.

doi:10.15585/mmwr.mm7107a1

Cited by 20 publications

(17 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Until now, pneumococcal vaccines have been developed as free CPS and protein carrier-conjugated CPS, which are currently licensed as the 23-valent pneumococcal polysaccharide vaccine (PPSV23) and the 10-valent or 13-valent pneumococcal conjugate vaccine (PCV10, PCV13), respectively. In response to other emerging serotypes beyond PCV13 due to the natural competence phenotype of this microorganism 20 , new PCV vaccines with broaden serotype, such as PCV15 or PCV20, are being tested in a range of clinical trials globally 21 , and have been already approved for use in adults in a few countries 22 , 23 . However, as the polysaccharides are per se T-cell independent antigen, insufficient immunogenicity not only of free purified CPS, but also of protein carrier-conjugated CPS has been described 24 .…”

Section: Introductionmentioning

confidence: 99%

A highly immunogenic vaccine platform against encapsulated pathogens using chimeric probiotic Escherichia coli membrane vesicles

et al. 2022

View full text Add to dashboard Cite

Vaccines against infectious diseases should elicit potent and long-lasting immunity, ideally even in those with age-related decline in immune response. Here we report a rational polysaccharide vaccine platform using probiotic Escherichia coli-derived membrane vesicles (MVs). First, we constructed a probiotic E. coli clone harboring the genetic locus responsible for biogenesis of serotype 14 pneumococcal capsular polysaccharides (CPS14) as a model antigen. CPS14 was found to be polymerized and mainly localized on the outer membrane of the E. coli cells. The glycine-induced MVs displayed the exogenous CPS14 at high density on the outermost surface, on which the CPS14 moiety was covalently tethered to a lipid A-core oligosaccharide anchor. In in vivo immunization experiments, CPS14+MVs, but not a mixture of free CPS14 and empty MVs, strongly elicited IgG class-switch recombination with a Th1/Th2-balanced IgG subclass distribution without any adjuvant. In addition, CPS14+MVs were structurally stable with heat treatment and immunization with the heat-treated MVs-elicited CPS14-specific antibody responses in mouse serum to levels comparable to those of non-treated CPS14+MVs. Notably, the immunogenicity of CPS14+MVs was significantly stronger than those of two currently licensed vaccines against pneumococci. The CPS14+MV-elicited humoral immune responses persisted for 1 year in both blood and lung. Furthermore, the CPS14+MV vaccine was widely efficacious in mice of different ages. Even in aged mice, vaccination resulted in robust production of CPS14-specific IgG that bound to the pneumococcal cell surface. Taken together, the present probiotic E. coli MVs-based vaccine platform offers a promising, generalizable solution against encapsulated pathogens.

show abstract

Section: Introductionmentioning

confidence: 99%

A highly immunogenic vaccine platform against encapsulated pathogens using chimeric probiotic Escherichia coli membrane vesicles

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The 2022 Advisory Committee on Immunization Practices (ACIP) recommendations for immunizations in adults aged 19 and older have been approved by the United States Centers for Disease Control and Prevention (CDC) 3. Significant updates include previously released recommendations for use of hepatitis B vaccination (HepB) in healthy adults, recombinant zoster vaccine (RZV) in immunocompromised adults, and pneumococcal conjugate vaccines (PCV15 and PCV20) in different age groups.…”

Section: Family Medicine — Immunizationsmentioning

confidence: 99%

UpToDate®

2022

The Nurse Practitioner

View full text Add to dashboard Cite

UpToDate ® and The Nurse Practitioner are collaborating to present select "What's New" content. UpToDate is an evidence-based, clinical support resource used worldwide by healthcare practitioners to make decisions at the point of care. For complete, current "What's New" content, or to become a subscriber for full content access, visit go.uptodate.com/np. "What's New" is free for all medical professionals.Disclaimer: This content is provided for reference purposes only and represents a portion of the UpToDate topic. Readers should not rely on the content or any information cited here as being applicable to specifi c patient circumstances. All topics are updated as new evidence becomes available and our peer review process is complete.

show abstract

“…In 2010, the American Society for Health System Pharmacists published a statement outlining the pharmacist's role in AMS, which includes providing and promoting vaccination to reduce infection 7 . Vaccine recommendations are standardized across our VA and derive from a variety of guidelines, including those of the Advisory Committee on Immunization Practices, 8 the Infectious Disease Society of America, 9 and the American Transplant Society 10 . To ensure SOT candidates meet vaccine recommendations prior to transplantation, the transplant CPP creates a personalized vaccination schedule for each patient by modifying our VA's standardized vaccine recommendation chart, and places it in the elecronic health record.…”

Section: Ams Activities Before Transplantationmentioning

confidence: 99%

Section: Vaccine Review and Administrationmentioning

confidence: 99%

Antimicrobial stewardship in solid organ transplantation: Perspective from a Veterans Affairs Medical Center

Felkner

Barnett

Misch

et al. 2022

Transplant Infectious Dis

View full text Add to dashboard Cite

Background The importance of antimicrobial stewardship (AMS) activities specifically focused on solid organ transplant (SOT) recipients is increasingly recognized. In 2014, the Veterans Health Administration (VHA) created national guidance and committed resources to establish AMS programs at Veterans Affairs (VA) medical centers across the country. However, the AMS implementation is at the discretion of individual VA centers. Methods We undertook an environmental scan of AMS activities in a tertiary care VA medical center. Results We describe AMS activities focused on SOT recipients. Strategies based on local epidemiology that leverage the electronic medical record together with engagement by transplant infectious diseases personnel are likely to be beneficial. Conclusion AMS in SOT recipients is challenging yet impactful. Strategies described here may be useful for AMS activities focused on the SOT population.

show abstract

Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2022

Cited by 20 publications

References 4 publications

A highly immunogenic vaccine platform against encapsulated pathogens using chimeric probiotic Escherichia coli membrane vesicles

A highly immunogenic vaccine platform against encapsulated pathogens using chimeric probiotic Escherichia coli membrane vesicles

UpToDate®

Antimicrobial stewardship in solid organ transplantation: Perspective from a Veterans Affairs Medical Center

Contact Info

Product

Resources

About